Arbutus Biopharma (ABUS) Sets New 12-Month Low at $2.19

Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) hit a new 52-week low during trading on Monday . The company traded as low as $2.19 and last traded at $2.20, with a volume of 6375 shares traded. The stock had previously closed at $2.35.

A number of brokerages recently commented on ABUS. Zacks Investment Research lowered Arbutus Biopharma from a “buy” rating to a “hold” rating in a research report on Friday. ValuEngine lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, BidaskClub upgraded Arbutus Biopharma from a “hold” rating to a “buy” rating in a research report on Tuesday, March 5th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $6.25.

The company has a quick ratio of 11.50, a current ratio of 12.75 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $129.05 million, a P/E ratio of -2.16 and a beta of 1.61.

Arbutus Biopharma (NASDAQ:ABUS) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.16). The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.18 million. Arbutus Biopharma had a negative return on equity of 95.26% and a negative net margin of 1,237.92%. As a group, equities research analysts expect that Arbutus Biopharma Corp will post -1.32 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of ABUS. Wells Fargo & Company MN grew its stake in Arbutus Biopharma by 46.9% during the 3rd quarter. Wells Fargo & Company MN now owns 68,063 shares of the biopharmaceutical company’s stock valued at $644,000 after acquiring an additional 21,737 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Arbutus Biopharma by 129.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 191,857 shares of the biopharmaceutical company’s stock valued at $1,813,000 after acquiring an additional 108,398 shares in the last quarter. BlackRock Inc. grew its stake in Arbutus Biopharma by 1.3% during the 3rd quarter. BlackRock Inc. now owns 2,422,221 shares of the biopharmaceutical company’s stock valued at $22,891,000 after acquiring an additional 31,078 shares in the last quarter. MetLife Investment Advisors LLC purchased a new stake in Arbutus Biopharma during the 3rd quarter valued at about $270,000. Finally, AQR Capital Management LLC grew its stake in Arbutus Biopharma by 142.3% during the 3rd quarter. AQR Capital Management LLC now owns 46,576 shares of the biopharmaceutical company’s stock valued at $440,000 after acquiring an additional 27,354 shares in the last quarter. Institutional investors own 42.59% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Arbutus Biopharma (ABUS) Sets New 12-Month Low at $2.19” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/13/arbutus-biopharma-abus-sets-new-12-month-low-at-2-19.html.

Arbutus Biopharma Company Profile (NASDAQ:ABUS)

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

Read More: What Are Treasury Bonds?

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.